反応式
[CH3:1][O:2][C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[N:9]1[CH2:14][CH2:13][N:12]([CH2:15][CH2:16][CH2:17][C:18]([O:20][CH2:21][C:22]2[CH:31]=[C:30]3[C:25]([CH2:26][CH2:27][C:28](=[O:32])[NH:29]3)=[CH:24][CH:23]=2)=[O:19])[CH2:11][CH2:10]1.[ClH:33]>>[ClH:33].[CH3:1][O:2][C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[N:9]1[CH2:10][CH2:11][N:12]([CH2:15][CH2:16][CH2:17][C:18]([O:20][CH2:21][C:22]2[CH:31]=[C:30]3[C:25]([CH2:26][CH2:27][C:28](=[O:32])[NH:29]3)=[CH:24][CH:23]=2)=[O:19])[CH2:13][CH2:14]1参加物
3
実験手順
(2-Oxo-1,2,3,4-tetrahydroquinolin-7-yl)methyl 4-(4-(2-methoxyphenyl)piperazin-1-yl)butanoate hydrochloride (39c) (Scheme 7) was prepared from the compound 38c according to the protocol described for the compound 39a (Example 49). The hydrochloride salt 39c gave satisfactory 1H NMR spectral data. White solid, 0.05 g (31%). MS (ESI): m/z=438.2 (M+H+).
出典と根拠
- ORDレコード
- ord-9c24b41c907a4a5386e87c2ab9273e29
- 出典データセット
- uspto-grants-2012_08
- 特許番号
- US08247420B2
関連ノート
読み込み中…